Definium Therapeutics (DFTX) Stock Soars 52% on Breakthrough Depression Trial Results

Key Highlights

• Shares of Definium Therapeutics climbed approximately 52% on June 22, 2026, following positive Phase 3 Emerge trial results for DT120 in treating major depressive disorder
• The experimental treatment demonstrated an 8.1-point advantage over placebo on the MADRS depression assessment at the six-week mark, with benefits emerging within the first week
• Safety data proved favorable — nearly all adverse events were classified as mild to moderate severity, without new safety concerns or elevated suicide risk
• The biotech company maintains approximately $411.6 million in available capital with no immediate financing requirements, and DT120 has received FDA Breakthrough Therapy status
• Several investment firms including Jefferies, RBC Capital, and Canaccord Genuity maintain positive ratings; one target price reached $44 earlier this month

Shares of Definium Therapeutics (DFTX) rocketed as high as 52% during Monday’s trading session following the company’s announcement that its Phase 3 Emerge clinical trial for DT120 successfully achieved its primary efficacy endpoint in major depressive disorder patients.

Definium Therapeutics, Inc. (DFTX)

In premarket activity, shares had already surged approximately 39% to reach $34.01. As the session progressed, the stock climbed even higher, crossing $37 per share — significantly surpassing its previous 52-week peak of $26.25.

The clinical study recruited adult patients diagnosed with major depressive disorder to evaluate a single 100 microgram oral dose of DT120, the company’s proprietary tablet formulation containing lysergide (LSD). Results demonstrated the trial achieved its primary objective with an 8.1-point improvement versus placebo on the Montgomery-Åsberg Depression Rating Scale at the six-week evaluation point.

The findings reached high statistical significance with a p-value under 0.0001. Notably, therapeutic benefits emerged within just one week of treatment and remained sustained throughout the 12-week observation period.

Additional secondary outcome measures reinforced the primary findings, including Clinical Global Impressions severity assessments, which similarly demonstrated meaningful improvement.

Regarding tolerability, the profile appeared highly favorable. Approximately 99% of treatment-related adverse events fell into mild or moderate categories, study withdrawal rates matched placebo levels, and investigators observed no novel safety issues or heightened suicidality — a particularly important consideration for antidepressant therapies.

Wall Street Support Was Already Established

Definium entered this data readout with substantial analyst backing. Investment firms including Jefferies, RBC Capital, Canaccord Genuity, and LifeSci Capital had all reaffirmed Buy recommendations during the weeks preceding this announcement.

One analyst, Francois Brisebois, elevated his price objective to $44 in early June, describing DT120 as a “de-risked” investment opportunity applicable to both anxiety and depressive disorders. Current consensus maintains a Buy recommendation with a $38 price target.

The company’s financial position remains robust. Definium reported approximately $411.6 million in available cash according to its most recent disclosure, eliminating any immediate capital-raising needs. Current projections suggest this financial cushion extends operations through 2028.

Additionally, DT120 has secured FDA Breakthrough Therapy Designation, potentially expediting the regulatory review process for future submission materials.

Looking Forward

Definium is currently conducting a second Phase 3 clinical trial named Ascend, which mirrors the Emerge study design. With one successful positive dataset now in hand, the company has established foundational evidence to support a future New Drug Application submission for major depressive disorder.

Competitor Compass Pathways (CMPS) also experienced share price gains on the same day, indicating the Emerge trial outcomes generated positive momentum throughout the psychedelic medicine sector.

Broader equity markets also traded positively, with the Nasdaq advancing 1.9% while the S&P 500 gained 1.1%.

Following Monday’s rally, Definium’s market capitalization reached approximately $2.67 billion.

The post Definium Therapeutics (DFTX) Stock Soars 52% on Breakthrough Depression Trial Results appeared first on Blockonomi.